Results 81 to 90 of about 580,459 (300)

Implantable Systems for Cardiovascular Treatment and Monitoring: Comparative Insights From Intracardiovascular and Extracardiovascular Technologies

open access: yesAdvanced Intelligent Systems, EarlyView.
A unifying device–cardiovascular interface framework is presented to classify implantable cardiovascular technologies as intracardiovascular blood‐contacting systems or extracardiovascular tissue‐only and blood‐handling architectures. Cross‐class comparison across shared semiquantitative criteria, including blood‐contact burden, biomimicry ...
Bergo Nicolò   +7 more
wiley   +1 more source

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac   +16 more
wiley   +1 more source

Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis.

open access: yesPLoS ONE, 2013
BackgroundHigh-dose therapy with autologous peripheral stem cell transplantation represents today the standard approach for younger multiple myeloma patients.
Alessandro Corso   +8 more
doaj   +1 more source

Final Analysis of the BRUIN Phase 1/2 Study Assessing the Safety and Efficacy of Pirtobrutinib Monotherapy in Patients With MCL

open access: yesAmerican Journal of Hematology, EarlyView.
ABSTRACT Pirtobrutinib, a highly selective, non‐covalent Bruton tyrosine kinase inhibitor (BTKi) previously demonstrated durable efficacy and tolerable safety following covalent (c) BTKi therapy in heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL).
Michael L. Wang   +36 more
wiley   +1 more source

A Comparison of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation for Acute Myeloblastic Leukemia [PDF]

open access: yesInternational Journal of Hematology-Oncology and Stem Cell Research, 2009
Introduction: Acute Myelogenous Leukemia (AML) is a clonal  malignant disease of hematopoietic tissue. The early use of  Hematopoietic Stem Cell Transplantation (HSCT) for AML was for patients with advanced stages of disease, usually while in relapse, in
Ardeshir Ghavamzadeh   +4 more
doaj   +1 more source

Diffusion-weighted imaging for the follow-up of patients after matrix-associated autologous chondrocyte transplantation

open access: yes, 2010
To evaluate the use of diffusion-weighted imaging (DWI) for the assessment of cartilage maturation in patients after matrix-associated autologous chondrocyte transplantation (MACT)
Welsch, G   +8 more
core   +1 more source

Intravascular Large B-cell Lymphoma Successfully Treated with Autologous Transplantation

open access: yes, 2021
• Intravascular large B-cell lymphoma is an aggressive disease with a poor outcome, and the use of autologous stem cell transplantation is still a matter of debate.
Zinzani P. L.   +4 more
core   +1 more source

Animal stroke models and outcome evaluation: A review

open access: yesAnimal Models and Experimental Medicine, EarlyView.
Rodents are the preeminent stroke model species. Large animal models exist too, but are poorly standardized. Ischemic and hemorrhagic experimental models are available, with the intraluminal filament model being predominant. Outcomes are evaluated via quantifying subjects' sensorimotor impairment, cognitive memory faculties, degree of cellular ...
Solsa Cariba   +2 more
wiley   +1 more source

The long-term effect of AHSCT on MRI measures of MS evolution: a five-year follow-up study

open access: yes, 2007
Using MRI, we measured disease activity and brain atrophy in nine multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (AHSCT) for a mean follow up of 63 months.
L. Bonzano   +13 more
core   +1 more source

Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?

open access: yesHematology/Oncology and Stem Cell Therapy, 2017
Relapse of Hodgkin lymphoma after autologous hematopoietic cell transplantation (autologous HCT) is a major therapeutic challenge. Its management, at least in younger patients, traditionally involves salvage chemotherapy aiming to achieve disease ...
Yogesh Jethava   +2 more
doaj   +1 more source

Home - About - Disclaimer - Privacy